Clinical Trials Logo

Large B-cell Lymphoma clinical trials

View clinical trials related to Large B-cell Lymphoma.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT05733650 Approved for marketing - Clinical trials for Large B-cell Lymphoma

Expanded Access Program for Epcoritamab

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this program is to provide investigational epcoritamab, an antibody also known as GEN3013 (DuoBody-CD3xCD20), in an expanded access setting for eligible patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) who have a high unmet medical need with no other treatment options. It is a requirement that patients do not qualify for an ongoing epcoritamab clinical program or are unable to participate due to logistical reasons. Access to investigational epcoritamab can be requested by contacting preapprovalaccessprograms@genmab.com.